STAT

2018 in limericks: The highs and lows from the life sciences

What a year it's been in the life sciences: CRISPR babies and IPOs galore, high-priced CAR-Ts and gene therapies. We remember it all with the 2018 edition of our year…

It’s been an eventful year in the life sciences, from the struggles of IBM Watson, to China’s twin CRISPR surprise, to a flurry of IPOs, to catching a serial killer with.)

Anda sedang membaca pratinjau, daftarlah untuk membaca selengkapnya.

Lainnya dari STAT

STAT4 mnt membacaSociety
Opinion: Professionalism Drives Health Care Workers To Treat Patients With Covid-19. We Mustn’t Jeopardize It
Americans admire health care workers, and that admiration has justifiably grown during this crisis. But we should realize that the professionalism underneath their work is fragile and needs to be…
STAT1 mnt membaca
STAT Plus: Pharmalittle: Gilead Faces Remdesivir Production Challenges; Will Scientists Run Out Of Covid-19 Trial Patients?
Gilead faces the challenge of scaling up production of remdesivir, its experimental #Covid19 drug that the whole world may want.
STAT4 mnt membaca
Opinion: Lost Opportunities From FDA, NIH Inaction When Sponsors Fail To Report Clinical Trial Results
Not enforcing the Food and Drug Administration Amendments Act puts Americans at greater risk of wasting money on useless medical products and being injured by unsafe ones.